Key statistics
On Friday, Gain Therapeutics Inc (GANX:NMQ) closed at 1.72, 93.26% above the 52 week low of 0.89 set on Aug 13, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.60 |
---|---|
High | 1.78 |
Low | 1.56 |
Bid | 1.73 |
Offer | 1.81 |
Previous close | 1.62 |
Average volume | 270.89k |
---|---|
Shares outstanding | 25.96m |
Free float | 24.66m |
P/E (TTM) | -- |
Market cap | 42.06m USD |
EPS (TTM) | -1.13 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
- Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update
- Gain Therapeutics Presents Data at 36ᵗʰ EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2
- Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
- Gain Therapeutics to Present at Michael J. Fox Foundation’s 16th Annual Parkinson’s Disease Therapeutics Conference
- Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024
- Gain Therapeutics to Participate at Upcoming Investor Conferences
- Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson’s Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers
- Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease
- Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson’s Disease Models Including Two Late-Breakers at Neuroscience 2024
- Gain Therapeutics to Participate at H.C. Wainwright 26th Annual Global Investment Conference
More ▼